Back to Search
Start Over
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study
- Source :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 61(7)
- Publication Year :
- 2015
-
Abstract
- Background. There is a need to prevent or minimize bone loss associated with antiretroviral treatment (ART) initiation. We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)–containing ART. Methods. This was a double-blind, placebo-controlled trial. ART-naive subjects with human immunodeficiency virus type 1 RNA load (viral load [VL]) >1000 copies/mL and R5 tropism were randomized to MVC 150 mg or TDF 300 mg once daily (1:1), stratified by VL
- Subjects :
- Microbiology (medical)
musculoskeletal diseases
Adult
Male
medicine.medical_specialty
Bone density
Anti-HIV Agents
Population
HIV Infections
Emtricitabine
Gastroenterology
Maraviroc
chemistry.chemical_compound
Bone Density
Cyclohexanes
Internal medicine
medicine
Humans
education
Pelvic Bones
Tenofovir
Darunavir
education.field_of_study
business.industry
virus diseases
Middle Aged
Triazoles
medicine.disease
Surgery
Osteopenia
Infectious Diseases
chemistry
HIV/AIDS
Ritonavir
Female
business
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 15376591
- Volume :
- 61
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Accession number :
- edsair.doi.dedup.....e7ceeb95b46eaab57187a76006535d11